Stockscreener 앱 받기
0.79
3.66%
-0.03
시간 외 거래:
.83
0.04
+5.06%
전일 마감가:
$0.82
열려 있는:
$0.806
하루 거래량:
44,337
Relative Volume:
0.01
시가총액:
$18.24M
수익:
-
순이익/손실:
$-16.28M
주가수익비율:
-0.0568
EPS:
-13.91
순현금흐름:
$-13.75M
1주 성능:
-5.69%
1개월 성능:
+3.72%
6개월 성능:
-0.03%
1년 성능:
-37.30%
1일 변동 폭
$0.79
$0.8375
1주일 범위
$0.75
$0.8816
52주 변동 폭
$0.281
$3.79
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
명칭
Pasithea Therapeutics Corp
전화
(702) 514-4174
주소
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.79 | 18.93M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Earnings Recap: Whats the beta of Pasithea Therapeutics Corp stockMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Fed Watch: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Certain Options of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
KTTA PE Ratio & Valuation, Is KTTA Overvalued - Intellectia AI
KTTA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Coastlands entities hold 2.39M shares in Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
KTTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Breakout Move: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising ratesPortfolio Return Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
What’s next for Pasithea Therapeutics Corp. stockTrade Entry Report & AI Enhanced Execution Alerts - mfd.ru
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice - TipRanks
Pasithea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CVI and Heights disclose 3.8% Pasithea (KTTA) stake via warrant holdings - Stock Titan
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network
Pasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative
Ameriprise discloses 8.4% Pasithea Therapeutics (NASDAQ: KTTA) stake - Stock Titan
Can Pasithea Therapeutics Corp. disrupt its industryQuarterly Market Summary & Daily Stock Trend Reports - mfd.ru
KTTA Should I Buy - Intellectia AI
Published on: 2026-02-12 18:27:19 - mfd.ru
Aug Mood: How does Pasithea Therapeutics Corp. correlate with NasdaqJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru
Published on: 2026-02-12 00:18:47 - mfd.ru
Why Pasithea Therapeutics Corp. stock is seen as undervaluedTrade Analysis Summary & AI Forecast for Swing Trade Picks - mfd.ru
What’s the beta of Pasithea Therapeutics Corp. stockWeekly Trading Summary & Precise Buy Zone Identification - mfd.ru
Why Pasithea Therapeutics Corp. Equity Warrant stock could be next big winnerJuly 2025 Price Swings & Daily Market Momentum Tracking - mfd.ru
Earnings Miss: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly pricedJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Dividend Watch: What is the Moat Score of Pasithea Therapeutics Corp Equity WarrantGDP Growth & Stock Market Timing Techniques - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Levels: Can Pasithea Therapeutics Corp disrupt its industryWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Meme Stocks: Can Beyond Meat Inc. navigate macro headwindsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Jobs Data: What is the long term forecast for Pasithea Therapeutics Corp stockJuly 2025 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Weekly Earnings: Can Pasithea Therapeutics Corp disrupt its industryQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Institution Moves: Can Alerus Financial Corporation withstand a market correctionBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Pasithea Therapeutics Corp. stock influenced by commodity prices2025 Historical Comparison & Consistent Profit Trading Strategies - Mfd.ru
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization - TipRanks
Fundamentals Check: Is POET benefiting from innovation trends2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Performance Recap: Should I average down on WRAP stockMarket Movers & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aug Shorts: Can Pasithea Therapeutics Corp sustain earnings growth2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
How does SWVL compare to its peersEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Published on: 2026-01-22 13:20:30 - baoquankhu1.vn
Aug Big Picture: Is Finward Bancorp benefiting from interest rate changes2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics regains Nasdaq compliance - MSN
New Highs: Can Pasithea Therapeutics Corp grow without external fundingJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - baoquankhu1.vn
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway - TipRanks
Pasithea provides updates on clinical trials for MEK inhibitor drug By Investing.com - Investing.com Canada
Pasithea provides updates on clinical trials for MEK inhibitor drug - Investing.com
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Investing News Network
Pasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced Cancer - Quiver Quantitative
Pasithea Therapeutics (NASDAQ:KTTA) Stock Rating Upgraded by Wall Street Zen - Defense World
How Pasithea Therapeutics Corp. Equity Warrant stock reacts to oil pricesJuly 2025 EndofMonth & Stepwise Trade Execution Plans - ulpravda.ru
How analysts rate Pasithea Therapeutics Corp. stock today2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Why hedge funds are buying Pasithea Therapeutics Corp. stock2025 Momentum Check & Verified Swing Trading Watchlists - ulpravda.ru
Pasithea Therapeutics Corp (KTTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pasithea Therapeutics Corp 주식 (KTTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
3.69%
0.68%
자본화:
|
볼륨(24시간):